Allogene Earnings Reports

Allogene Therapeutics reported a Q4 2024 net loss of $59.9 million, with no revenue recognized for the quarter. The company ended the year with $373.1 million in cash and investments, projecting its cash runway into the second half of 2026. R&D expenses totaled $45.0 million, including $5.6 million in stock-based compensation, while general and administrative expenses were $15.5 million, including $7.3 million in stock-based compensation.

Allogene Therapeutics reported its Q3 2024 financial results, highlighting the progress of its allogeneic cell products, including cema-cel, ALLO-316, and ALLO-329. The company ended the quarter with $403.4 million in cash, cash equivalents, and investments, projecting a cash runway into the second half of 2026.

Allogene Therapeutics reported a net loss of $66.4 million for the second quarter of 2024 and ended the quarter with $444.6 million in cash, cash equivalents, and investments. The pivotal Phase 2 ALPHA3 trial was initiated in June 2024, and the IND application for ALLO-329 is on track for Q1 2025.

Allogene Therapeutics reported a net loss of $65.0 million for the first quarter of 2024 and ended the quarter with $397.3 million in cash, cash equivalents and investments. The company expects its cash runway to fund operations into 2026.

Allogene Therapeutics ended 2023 with $448.7 million in cash, cash equivalents and investments and anticipates its cash runway will fund operations into 2026. Start-up activities for the ALPHA3 trial are underway and the trial is expected to begin in mid-2024. Initial data readout from Phase 1 ALPHA2 CLL cohort (n=12) is projected by year-end 2024. ALLO-329 is expected to enter Phase 1 clinical trials in early 2025.

Allogene Therapeutics reported $497.7 million in cash, cash equivalents, and investments as of September 30, 2023. Net loss for the third quarter of 2023 was $61.3 million, or $0.37 per share.

Allogene Therapeutics reported a net loss of $78.0 million for Q2 2023 and ended the quarter with $544.5 million in cash, cash equivalents and investments. The company is advancing its allogeneic CAR T clinical trials, with enrollment ongoing in the ALPHA2 and EXPAND Phase 2 trials in LBCL. The cash runway is projected to extend into 2H 2025.

Allogene Therapeutics reported its first quarter financial results, highlighting progress in clinical programs, talent acquisition, and financial management. The company ended the quarter with $514 million in cash and expects the cash runway to extend into Q2 2025.

Allogene Therapeutics reported a net loss of $94.8 million for the fourth quarter of 2022, with $576.5 million in cash, cash equivalents, and investments as of December 31, 2022. The company highlighted progress in its allogeneic CAR T programs, including the initiation of a pivotal Phase 2 trial for ALLO-501A and promising data from its BCMA and CD70 programs.

Allogene Therapeutics reported the initiation of their Phase 2 ALPHA2 trial and ended the third quarter with $637 million in cash, cash equivalents and investments. The company will host a Research & Development Showcase on November 29, 2022.

Allogene Therapeutics reported its second quarter financial results, highlighting the anticipated U.S. FDA clearance for a potential pivotal Phase 2 trial of ALLO-501A and the operational status of its commercial-scale manufacturing facility, Cell Forge 1 (CF1). The company ended the quarter with $686 million in cash, cash equivalents, and investments.

Allogene Therapeutics reported a net loss of $79.9 million for the first quarter of 2022 and ended the quarter with $733.1 million in cash, cash equivalents, and investments. The company is progressing with its pipeline, including the planned initiation of the pivotal Phase 2 ALPHA2 trial of ALLO-501A in R/R Large B Cell Lymphoma in mid-2022.

Allogene Therapeutics reported a net loss of $74.9 million for the fourth quarter of 2021. Clinical trials have resumed following the removal of the FDA clinical hold in January 2022. The company ended the year with $810 million in cash, cash equivalents and investments.

Allogene Therapeutics reported a net loss of $78.2 million for the third quarter of 2021. As of September 30, 2021, the company's cash, cash equivalents, and investments totaled $861.7 million. The FDA has placed a hold on the Company’s AlloCAR T clinical trials and the company is working to resolve the hold.

Allogene Therapeutics reported a net loss of $70.9 million for the second quarter of 2021. The company ended the quarter with $913.2 million in cash, cash equivalents, and investments.

Allogene Therapeutics reported a net loss of $33.0 million, or $0.25 per share, for the first quarter of 2021. The company ended the quarter with $964.2 million in cash, cash equivalents, and investments. Significant clinical and regulatory progress was made across the AlloCAR T portfolio, including the start of the first solid tumors study.

Allogene Therapeutics reported fourth quarter and full year 2020 financial results, highlighting the progress of AlloCAR T candidates, IND submissions, and the completion of Cell Forge 1. The company ended the year with $1.0 billion in cash, cash equivalents, and investments.

Allogene Therapeutics reported its third quarter financial results, highlighting the advancement of its AlloCAR T pipeline and upcoming data presentations. The company ended the quarter with $1.0 billion in cash, cash equivalents, and investments.

Allogene Therapeutics reported positive initial Phase 1 results from the ALLO-501 ALPHA Trial, initiated the Phase 1 portion of the ALPHA2 Trial for ALLO-501A, and completed the initial dose escalation portion of the Phase 1 ALLO-715 UNIVERSAL Trial. The company ended the quarter with $1.1 billion in cash, cash equivalents, and investments.

Allogene Therapeutics reported its first quarter financial results, highlighting progress in its AlloCAR T therapy development, including upcoming presentations and trial initiations. The company ended the quarter with $553 million in cash, cash equivalents, and investments.

Allogene Therapeutics reported fourth-quarter financial results, including cash, cash equivalents, and investments of $588.9 million. Research and development expenses were $49.4 million, and general and administrative expenses were $15.2 million. The net loss for the quarter was $61.0 million, or $0.58 per share.